NEW YORK (GenomeWeb News) – Bruker reported after the close of the market Wednesday that its revenues in the second quarter were up 8 percent year over year, rising to $454.9 million, compared to $420.7 million in Q2 2012.

The results beat the average Wall Street estimate of $426.4 million, as the company saw "weakness in some key markets partially offset by diversified pockets of growth," Bruker President and CEO Frank Laukien said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.

Oct
10
Sponsored by
PerkinElmer

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.